<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432598</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-206</org_study_id>
    <secondary_id>CTR20170361</secondary_id>
    <nct_id>NCT03432598</nct_id>
  </id_info>
  <brief_title>Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in&#xD;
      combination with standard platinum-based chemotherapy in participants with advanced NSCLC or&#xD;
      SCLC. The 4 cohorts will be enrolled concurrently including non-squamous NSCLC Cohort,&#xD;
      squamous NSCLC Cohort A, squamous NSCLC Cohort B and SCLC Cohort. Participants with a mixed&#xD;
      adenocarcinoma and squamous cell NSCLC will be allocated to one of the NSCLC cohorts based on&#xD;
      the predominant histopathological profile. (e.g., participants with adenocarcinoma component&#xD;
      accounting for &gt; 50% will be allocated to non-squamous NSCLC cohort.). Participants with&#xD;
      squamous NSCLC will be sequentially enrolled into either of the 2 squamous NSCLC cohorts by&#xD;
      the trial stage i.e. the sequence of the enrollment for the squamous NSCLC cohorts will be as&#xD;
      Cohort A safety run-in Stage, followed by Cohort B safety run-in Stage, Cohort A&#xD;
      dose-expansion stage and Cohort B dose-expansion Stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2017</start_date>
  <completion_date type="Actual">December 21, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate (ORR) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events (AEs) according to NCI-CTCAE Version 4.03</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) - defined as the time from the first determination of a confirmed objective response according to RECIST v1.1 until the first documentation of progression or death, whichever comes first</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) - defined as the time from the date of first dose of study treatment to the date of first documentation of disease progression using RECIST v1.1 or death, whichever occurs first</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) - defined as the proportion of participants who achieve CR, PR and SD using RECIST v1.1</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluations of BGB-A317 in combination with chemotherapy: including but not limited to Ctrough</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-BGB-A317 antibody: immunogenic responses to BGB-A317 will be assessed to determine occurrence of anti-drug antibody.</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The abnormality of laboratory tests according to NCI CTCAE Version 4.03</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Locally Advanced Lung Cancer; Metastatic Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Non-squamous NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 of each 21-day (3 weeks) cycle: Tislelizumab + pemetrexed + cisplatin 75 mg/m²/day IV (or carboplatin AUC 5).&#xD;
Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles.&#xD;
Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Squamous NSCLC Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab every 3 weeks (Q3W) + paclitaxel + cisplatin (or carboplatin), Q3W.&#xD;
Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles.&#xD;
Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Squamous NSCLC Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab Q3W on Day 1 + gemcitabine on Day 1 and Day 8 + cisplatin IV (or carboplatin) on Day 1.&#xD;
Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles.&#xD;
Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab Q3W on Day 1, etoposide on Days 1, 2, and 3 + cisplatin (or carboplatin) on Day 1.&#xD;
Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles.&#xD;
Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Administered 200 mg intravenously (IV) as specified in the treatment arm</description>
    <arm_group_label>Non-squamous NSCLC</arm_group_label>
    <arm_group_label>Squamous NSCLC Cohort A</arm_group_label>
    <arm_group_label>Squamous NSCLC Cohort B</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered 175 mg/m² IV as specified in the treatment arm</description>
    <arm_group_label>Squamous NSCLC Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered 1250 mg/m² IV as specified in the treatment arm</description>
    <arm_group_label>Squamous NSCLC Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Administered 100 mg/m2 IV as specified in the treatment arm</description>
    <arm_group_label>SCLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Administered 500 mg/m² IV as specified in the treatment arm</description>
    <arm_group_label>Non-squamous NSCLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered 75 mg/m²/day IV as specified in the treatment arm</description>
    <arm_group_label>Non-squamous NSCLC</arm_group_label>
    <arm_group_label>SCLC</arm_group_label>
    <arm_group_label>Squamous NSCLC Cohort A</arm_group_label>
    <arm_group_label>Squamous NSCLC Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered AUC 5 as specified in the treatment arm</description>
    <arm_group_label>Non-squamous NSCLC</arm_group_label>
    <arm_group_label>SCLC</arm_group_label>
    <arm_group_label>Squamous NSCLC Cohort A</arm_group_label>
    <arm_group_label>Squamous NSCLC Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18-75 years on the day of signing informed consent.&#xD;
&#xD;
          2. Have histologically or cytologically confirmed locally advanced or metastatic&#xD;
             non-squamous NSCLC, squamous NSCLC, or extensive-stage SCLC.&#xD;
&#xD;
             Note: Participants with mixed adenosquamous carcinoma may also be enrolled on a&#xD;
             case-by-case basis after discussion with the medical monitors.&#xD;
&#xD;
          3. Have had no prior systemic therapy for advanced or metastatic disease. Prior&#xD;
             neoadjuvant/adjuvant therapy or chemoradiation therapy with curative intent should&#xD;
             have been completed at least 6 months prior to documentation of recurrence of disease.&#xD;
&#xD;
          4. Participants must be able to provide fresh or archival tumor tissues (formalin-fixed&#xD;
             paraffin-embedded [FFPE] blocks or at least 10 unstained FFPE slides) with an&#xD;
             associated pathological report.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Participants with a sensitizing mutation in EGFR gene or an ALK fusion oncogene&#xD;
             (specifically for participants with non- squamous NSCLC). Participants with unknown&#xD;
             mutation/fusion status of EGFR and/or ALK must take the respective test at the&#xD;
             investigational sites (or other designated sites) prior to enrolment.&#xD;
&#xD;
          2. Prior malignancy active within the previous 2 years exceptions include the tumor under&#xD;
             investigation in this trial, and locally recurring cancers that have undergone&#xD;
             curative treatment, such as resected basal or squamous cell skin cancer, superficial&#xD;
             bladder cancer or carcinoma in situ of the cervix or breast&#xD;
&#xD;
          3. Prior therapies targeting PD-1, PD-L1 or PD-L2&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Tumor Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>133500</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaingsu People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin University First Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>132000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang Z, Zhao J, Ma Z, Cui J, Shu Y, Liu Z, Cheng Y, Leaw SJ, Wu Y, Ma Y, Tan W, Ma X, Zhang Y, Wang J. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Lung Cancer. 2020 Sep;147:259-268. doi: 10.1016/j.lungcan.2020.06.007. Epub 2020 Jun 20. Erratum in: Lung Cancer. 2021 Aug;158:166-167.</citation>
    <PMID>32769013</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

